Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$8.77M$8.77M−30.7% vs Q1 2019 Net Income-$16.53M-$16.53MN/M vs Q1 2019 EPS Diluted-$0.49-$0.49N/M vs Q1 2019 Operating Income-$13,861,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,768,000N/M Margins · derivedOperating margin-158.1%−54.7 pt vs Q1 2019
Net margin-188.6%−72.1 pt vs Q1 2019
ended Mar 31, 2020 · filed May 5, 2020 · 35 d after period end